NEW YORK (GenomeWeb) – Interpace Diagnostics reported today that its third quarter revenues rose 27 percent amid increased demand and reimbursement for its thyroid assays.

For the three-month period ended Sept. 30, Interpace's revenues climbed to $4.2 million from $3.3 million in the same period a year earlier. The company attributed the growth primarily to higher sales and reimbursement of its ThyGenX and ThyraMir tests for the diagnosis of thyroid cancer in patients with indeterminate thyroid nodules.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Jun
05

This webinar will discuss how Sanofi used literature mining to annotate the association of human leukocyte antigen (HLA) alleles with diseases and drug hypersensitivity as part of a multiple sclerosis (MS) biomarker discovery project.

Jun
14

This webinar will discuss an effort underway at the University of North Carolina Medical Center's to overcome limitations in the hematological genomic testing workflow with artificial intelligence (AI) from Sophia Genetics.

Jun
19

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Jun
26

This webinar outlines a study that sought to characterize the landscape of alternative polyadenylation (APA) in the lung cancer transcriptome in order to gain insight into the role of APA in cancer progression.